Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.
Saved in:
| Title: | Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer. |
|---|---|
| Authors: | Kim D; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Chung H; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Abed M; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Ma J; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Molden N; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Shim C; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Rajendran D; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Yen J; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Jeong J; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Levy A; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Yaniz-Galende E; Institut Gustave Roussy, Villejuif, France., Blanc-Durand F; Institut Gustave Roussy, Villejuif, France.; GINECO Group for Early Phase Studies (GINEGEPS), Paris, France., Desauw C; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France.; Centre Hospitalier Régional Universitaire de Lille - Hôpital Hurie, Lille, France., Follana P; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France.; Centre Antoine Lacassagne, Nice, France., Bonichon-Lamichhane N; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France.; Clinique Tivoli, Bordeaux, France., Oudard S; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France.; European Georges Pompidou Hospital, Paris, France., D'Hondt V; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France.; Institut du Cancer de Montpellier, Montpellier, France., Gavoille C; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France.; Centre Alexis Vautrin, Vandœuvre-lès-Nancy, France., Jandial DD; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu JF; Dana Farber Cancer Institute, Boston, MA, USA., Simpkins F; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA., Randall LM; Gynecologic Oncology Clinical Research and Gynecologic Cancer Service Line, Inova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA., Leary A; Institut Gustave Roussy, Villejuif, France.; GINECO Group for Early Phase Studies (GINEGEPS), Paris, France.; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du Sein (GINECO), Paris, France., Lackner MR; Zentalis Pharmaceuticals Inc., San Diego, CA, USA., Harismendy O; Zentalis Pharmaceuticals Inc., San Diego, CA, USA. oharismendy@zentalis.com. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2026 May 30; Vol. 10 (1). Date of Electronic Publication: 2026 May 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-026-01519-6 |
